London
Roots Analysis has announced the addition of “Neoantigen Targeted Therapies, 2019-2030” report to its list of offerings.
The use of neoantigens
in therapy has demonstrated the ability to elicit a strong T cell mediated
immune response. Several therapy candidates are being investigated both as
monotherapies and in combination with various immune checkpoint inhibitors,
such as atezolizumab, durvalumab, ipilimumab, and nivolumab. Of these, certain pipeline
candidates have already entered mid to late-stage (phase II and above) trials and
are anticipated to enter the market over the next 5-10 years.
To
order this 320+ page report, which features 110+ figures and 140+ tables,
please visit this - https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html
Key
Market Insights
Over 150+ candidate therapies in the development pipeline
Nearly 13% of the
pipeline therapies are being developed for the treatment of GI cancers,
followed by lung cancer (11%). Examples of molecules being developed for the
aforementioned indications include (in alphabetical order, no specific
selection criteria) MicOryx, NCI-4650, and Tedopi®.
1,100+ patents filed / granted in 2018
In fact, more than 6,000 patents were filed / granted related
to neoantigen targeted therapies, since 1978. Based on existing intellectual
property, the R&D activity was observed to be concentrated in the US. Other
key regions with significant intellectual capital include (in decreasing
order of number of patents filed / granted) Australia, Europe, China, and Canada.
Close to USD 7.5 billion invested by both private and
public investors, since 2014
Around USD 3,200 million was raised through venture capital
financing, representing around 43% of the total capital raised by industry
players in the given time period (till April 2019). Further, in the last five
years, there have been 10 IPOs accounting for more than 800 million in
financing of neoantigen related initiatives.
Companies are collaborating actively for the advancement of
clinical trials
Majority of the abovementioned agreements were observed to
be focused on conducting Phase I / Phase II clinical studies of neoantigen
targeted therapies for the treatment of different cancer indications. Agreements
signed for research purposes (19%) were also observed to be popular among
industry stakeholders, during 2014-2019 (till April).
It is worth noting that between the period 2014-2019, over
150 research articles were published related to neoantigen targeted therapies.
Further, more than 190 review articles have been published related to this
upcoming field.
Therapies using personalized neoantigens are anticipated to
increase at a CAGR of over 60% between 2024 and 2030
This growth is anticipated to be primarily driven by the reduced
risk of adverse effects and improved efficacy of personalized therapies.
North America (primarily the US) and Europe are expected to capture the
majority share by 2030, in terms of the sales-based revenues.
To
request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/257/request-sample.html
Key Questions Answered
§ What are the prevalent trends related to R&D activity
focused on neoantigen based therapies?
§
§
§
§
§
§
§
§
The USD 3 billion (by 2030)
financial opportunity within the neoantigens market has been analyzed across
the following segments:
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
The report features
inputs from eminent industry stakeholders, according to whom neoantigen targeted
therapies are expected to be the next big step in cancer immunotherapy. Similar
to CAR-T cell therapies, these therapies have, so far, demonstrated significant
therapeutic potential and promising clinical outcomes. The report includes
detailed transcripts of discussions held with the following experts:
§ Gabriel
Nistor (Chief Science Officer, AIVITA Biomedical)
§ Ella
Sorani (Vice President Research and Development, BioLineRx)
§
The research covers
detailed profiles, featuring an overview of the company, its financial
information (if available), and a
description of its product(s), highlighting type of therapy, current
development status, and key preclinical / clinical trial results. Each profile
also includes a list of recent developments, and an informed opinion on the
likely strategies that may be adopted by these players to fuel growth in the
foreseen future.
§
§
§
§
§
§
§
§
§
§
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html or email sales@rootsanalysis.com
You may also be
interested in the following titles:
1. T-Cell Immunotherapies Market (4th Edition), 2019-2030
2. Novel Immuno-Oncology Biomarker
Testing Market,
2019-2030
3. Companion Diagnostics Market (2nd Edition), 2019-2030
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
